Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007Decision ResourcesMay 3, 2007 23 Pages - SKU: DECR1492605 |
| Countries covered: United States, Europe In the first quarter of 2007, political intervention in drug pricing and reimbursement in the world's major pharmaceutical markets greatly increased. In the United States, for example, a new Democratic majority in Congress is intent on curbing the prices of branded medicines and facilitating the launch of generic drugs. In the United Kingdom, a complete overhaul of the country's pricing and reimbursement system has been proposed. The goal in all major pharmaceutical markets is to cut health care costs, and the pharmaceutical industry is an easy target. Questions Answered in This Spectrum Report:
|
Additional Information
Scope:
- First quarter news in 2007: major events in the pharmaceutical pricing, reimbursement, and prescribing environment in the United States, Europe (France, Germany, Italy, Spain, and the United Kingdom), and Japan.
- Cost-containment programs: legislation that has been proposed in the United States and elsewhere to reduce drug expenditures and make medication more affordable to patients.
- Outlook: our assessment of the implications of these events for the pharmaceutical industry in the major markets under study.
Organizations
- Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS; French Agency for the Safety of Health Products)
- Agence Technique de l’Information sur l’Hospitalisation
- Agenzia Italiana del Farmaco (AIFA; Italian Pharmaceutical Agency)
- Biotechnology Industry Organization (BIO)
- Bundesfachverband der Arzneimittelhersteller (BAH; Federal Association of Pharmaceutical Manufacturers)
- Bundesverband der Betriebskrankenkassen (BKK; Federal Association of Occupational Health Insurance Funds)
- Bundesvereinigung Deutscher Apothekerverbände (ABDA; Federal Union of German Pharmacists’ Associations)
- Centers for Medicare and Medicaid Services (CMS)
- Comité Economique des Produits de Santé
- Congressional Budget Offi ce (CBO)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- European Network for Health Technology Assessment (HTA)
- Farmaindustria
- Federación Empresarial de Farmaceúticos Españoles (FEFE; Business Federation of Spanish Pharmacists)
- Federal Trade Commission
- Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ)
- Gemeinsamer Bundesausschuß der Ärzte, Zahnärzte, Krankenhäuser und Krankenkassen (GBA; Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds)
- Gesetzliche Krankenversicherung (GKV; statutory health insurance)
- Haute Autorité de Santé (HAS; National Health Authority)
- House Committee on Oversight and Government Reform
- House Energy and Commerce Committee’s Subcommittee on Health
- Institut National du Cancer (INCa; National Cancer Institute)
- Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG; Institute for Quality and Economy in the Health Care System)
- Japan Generic Pharmaceutical Manufacturers Association (JGPMA)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Kassenärztliche Bundesvereinigung (KBV; Federal Union of Health Insurance Fund Physicians)
- Medicaid
- Medicare
- National Health Service (NHS)
- National Institute for Health and Clinical Excellence (NICE)
- Office of Fair Trading (OFT)
- Pharmaceutical Care Management Association
- Pharmaceutical Price Regulation Scheme (PPRS)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Servizio Sanitario Nazionale (SSN; National Health Service)
- Sistema Nacional de Salud (SNS; National Health System)
- Abbott
- Amgen
- Apotex
- AstraZeneca
- Bristol-Myers Squibb
- Express Scripts
- Genentech
- GlaxoSmithKline
- IMS Health
- Roche
- Sanofi -Aventis
- Schering-Plough
- Servier
- Takeda
- UCB
More Europe Pricing Reports
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure by
GBI Research
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, ...
The Outlook for Pharmaceuticals in Central & Eastern Europe (pdf/xls) by
Espicom Healthcare Intelligence
The pharmaceutical market of Central & Eastern Europe is estimated at US$63.6 billion at retail prices in 2011; it is expected to reach US$104.2 billion ...
The Outlook for Pharmaceuticals in Northern Europe (pdf/xls) by
Espicom Healthcare Intelligence
The Northern European countries are projected to represent a combined pharmaceutical market value of over US$26 billion at retail prices by 2016.
...
The Pharmaceutical Market: Czech Republic (pdf/xls) by
Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
The Pharmaceutical Market: Hungary (pdf/xls) by
Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
See all reports like this >>
More Europe Reports
A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
See all reports like this >>
Related Markets
- Insurance & Managed Care
- Medicare & Medicaid
- Pharmaceuticals
- Generics Drugs
- Regulation & Policy
- Prescription Drugs
- Pricing
Pricing Reports
- Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Pricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
- Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times
